Prevail Therapeutics — Investor Presentation (January 2020)
30 slides from Prevail Therapeutics's investor presentation, Jan 13, 2020
Slide 1: Corporate Presentation January 2020
Corporate Presentation JANUARY 2020
Slide 2: Disclaimer
Disclaimer Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Prevail Therapeutics, Inc.’s (“Prevail”) own internal estimates and research
Slide 3: Prevail Therapeutics overview
Prevail Therapeutics overview • PR001 Phase 1/2 PROPEL trial for Parkinson’s with GBA mutation (PD-GBA) Large Market & Near-Term currently recruiting; PD-GBA affects >90K Americans Value Inflection for PR001 • Potential for rapid proof-of-concept for PR001 in neuronopathic Gaucher disease; IND activ
Slide 4: Rapid execution in developing gene therapies for patients with urgent unmet needs
Rapid execution in developing gene therapies for patients with urgent unmet needs 2017 2018 2019 AUGUST 2017: MARCH 2018: MARCH 2019: JUNE 2019: Seed financing and $75M Series A $50M Series B $125M IPO REGENXBIO license OCTOBER 2017: MAY 2018: MAY 2019: OCTOBER 2019: Lab space secured REGENXBIO seco
Slide 5: Management and Board of Directors
Management and Board of Directors Experienced Management Team Board of Directors Francois Nader, MD Asa Abeliovich, Non-Executive Chairman Brett Kaplan, MD MD, PhD Chief Financial Officer CEO and Founder Asa Abeliovich, MD, PhD CEO and Founder Tim Adams Independent Yong Dai, PhD Carl Gordon, PhD, CF
Slide 6: Pipeline of disease-modifying AAV9 gene therapies for neurodegenerative diseases
Pipeline of disease-modifying AAV9 gene therapies for neurodegenerative diseases Stage of Development Upcoming Programs Indication Approach Milestones Discovery Preclinical Phase 1/2 Pivotal GBA1 • Interim Phase 1/2 data PD-GBA IND Active Gene Transfer in 2H of 2020 PR001 Neuronopathic GBA1 • Phase
Slide 7: Precision genetic medicine approach to neurodegenerative diseases
Precision genetic medicine approach to neurodegenerative diseases Mutated Gene Disease I N F L A M M A T I O N S U B S T R A T E A C C U M U L A T I O N D Y S F U N C T I O N A L L Y S O S O M E P A T H W A Y P R O T E I N C E L L T O X I C I T Y A G G R E G A T I O N • Human genetic studies have id
Slide 8: AAV9 is well-suited to deliver functional genes or gene knockdown to the CNS
C O N F I D E N T I A L 7 AAV9 is well-suited to deliver functional genes or gene knockdown to the CNS Viral transduction and Gene cargo AAV9 delivery vector CNS administration transgene expression • AAV9-based therapy has shown transformative efficacy and safety and is now approved for SMA • The ef
Slide 9: PR001 overview
PR001 overview • AAV9 viral vector delivering the GBA1 gene, which encodes PR001 glucocerebrosidase (GCase) Route of • Single intra-cisterna magna (ICM) injection Administration • Parkinson’s disease with at least one GBA1 mutation (PD-GBA) o Earlier disease onset, more rapid progression, and higher
Slide 10: Parkinson's disease
Parkinson’s disease Prodromal Period After Clinical Diagnosis Of PD • Early disease manifests with non-motor and subtle motor symptoms • With disease progression motor symptoms worsen Psychosis Complications and cognitive & behavioral symptoms emerge disability Fluctuations of Dyskinesia • Benefit o
Slide 11: PD-GBA and neuronopathic GD are a continuum of pathology
PD-GBA and neuronopathic GD are a continuum of pathology with the same underlying genetic mechanism Number and severity of GBA1 mutations ➜ Decreasing enzyme activity ➜ Increasing disease severity 1 1 2 2 0 mild / moderate severe mild / moderate severe mutations mutation mutation mutations mutat
Slide 12: PR001 mechanism of action in PD-GBA
PR001 mechanism of action in PD-GBA Parkinson’s PR001 Disease Treated WITH GBA1 MUTATION C O N F I D E N T I A L 12
Slide 13: PR001 CBE mouse model efficacy results
PR001 CBE mouse model efficacy results Activity and substrate reduction Activity and substrate reduction Efficacy (CBE dose-ranging efficacy study) (CBE 6-month efficacy study) (CBE dose-ranging efficacy study) GCase Activity GCase Activity Astrogliosis (glial scarring) GluSph GluSph Rotarod Means a
Slide 14: PR001 genetic mouse model efficacy results
PR001 genetic mouse model efficacy results Activity Substrate reduction Efficacy GCase Activity GluSph Beam Walk • PR001 increased GCase enzyme • 4L/PS-NA mice exhibited glycolipid • 4L/PS-NA mice exhibited motor activity (cortex) accumulation behavior dysfunction • PR001 suppressed lipid accumulati
Slide 15: PR001 safety and biodistribution in NHPs
PR001 safety and biodistribution in NHPs NHP biodistribution with ICM delivery Frontal Cortex 0.00e+00 9.93e+01 2.55e+05 Vector Genomes Hippocampus 0.00e+00 4.68e+03 5.81e+04 • NHP high dose equivalent to per ug DNA tissue starting clinical dose for Periventricular Tissue 0.00e+00 5.00e+02 2.17e+03
Slide 16: PR001 PD-GBA PROPEL Phase 1/2 trial
PR001 PD-GBA PROPEL Phase 1/2 trial Randomized, double-blind, sham procedure-controlled Single ICM 3 month 12 month 5-year safety and injection biomarker readout clinical readout clinical follow-up PD-GBA Patients PR001 Low Dose vs. Placebo (N=8, 6:2) • Single or biallelic GBA1 mutations • Moderate
Slide 17: Goal of PR001 treatment is to restore GCase activity
Goal of PR001 treatment is to deliver the GBA1 gene to restore GCase activity in PD-GBA patients GCase Enzyme Activity (Illustrative) Pre-PR001 Treatment Goal of PR001 Treatment ~70-80% - GBA ~50% PR001 PD Upside of PR001 100% Treatment • Human genetics suggest increasing GCase activity by 20-30% of
Slide 18: PR001 Type 2 Gaucher disease PROVIDE Phase 1/2 trial
PR001 Type 2 Gaucher disease PROVIDE Phase 1/2 trial Open label Single ICM 3-6 month 12 month 5-year safety and injection biomarker readout clinical readout clinical follow-up Type 2 Gaucher Patients • Infants 0-24 months old • Biallelic GBA1 mutations • Neurological signs & symptoms PR001 (Open lab
Slide 19: PR001 Type 3 Gaucher disease PROGRESS Phase 1/2 trial
PR001 Type 3 Gaucher disease PROGRESS Phase 1/2 trial Planned, open label Single ICM 3-6 month 12 month 5-year safety and injection biomarker readout clinical readout clinical follow-up Type 3 Gaucher Patients • Children 1-12 years old • Biallelic GBA1 mutations • Neurological signs & symptoms PR001
Slide 20: PR001 market opportunity
PR001 market opportunity PD-GBA Neuronopathic GD • Type 2 Gaucher: Severe progressive neurologic • PD patients with at least one GBA1 mutation Disease disease; mortality by age 2 • Earlier onset, faster progression, and higher Overview • Type 3 Gaucher: Juvenile or adult onset with prevalence of dem
Slide 21: PR006 overview
PR006 overview PR006 • AAV9 viral vector delivering the GRN gene, which encodes progranulin Route of • Single intra-cisterna magna (ICM) injection Administration • Frontotemporal dementia with GRN mutation (FTD-GRN) Lead Indications o Rapidly progressive dementia impacting behavior and language o Le
Slide 22: FTD-GRN is caused by progranulin deficiency
Frontotemporal dementia with GRN mutation is caused by progranulin deficiency Healthy Brain FTD-GRN N E U R O N S U R V I V A L N E U R O N A L C E L L D E A T H N O R M A L R E D U C E D • FTD pathology includes P R O G R A N U L I N P R O G R A N U L I N neurodegeneration and L Y S O S O M A L inf
Slide 23: Number of GRN mutations causes varying degrees of progranulin deficiency
Number of GRN mutations causes varying degrees of progranulin deficiency resulting in spectrum of disease Number of GRN mutations žœ Decreasing progranulin âžœ Increasing disease severity 0 1 2 mutation mutations mutations (Heterozygous) (Homozygous) Healthy Frontotemporal Neuronal Ceroid Individual
Slide 24: PR006 efficacy in human FTD-GRN neuronal cultures
PR006 efficacy in human FTD-GRN neuronal cultures iPSC-derived neurons from Secreted progranulin Progranulin Secreted expression progranulin Cathepsin Secreted D maturation progranulin Insoluble TDP-43 levels FTD-GRN mutation carriers 0.6 n Control 0.6 n 0.6 i o i o Control Control a t a t entration
Slide 25: PR006 efficacy in Grn knockout mice
PR006 efficacy in Grn knockout mice Progranulin expression Substrate reduction Neuroinflammation Progranulin mRNA Lipofuscin accumulation Neuroinflammation (cerebral cortex) (hippocampus) (Tnf mRNA) (cerebral cortex) • PR006 dose-dependently increased • PR006 dose-dependently • PR006 treatment reduc
Slide 26: PR006 safety and biodistribution in NHPs
PR006 safety and biodistribution in NHPs Progranulin Expression in CSF Results * • PR006 administration resulted in widespread transduction in the CNS t and periphery, and elevated 2—Excipien progranulin protein levels in the CSF from • No adverse PR006-related findings 1—Change (clinical and histop
Slide 27: PR006 FTD-GRN PROCLAIM Phase 1/2 trial
PR006 FTD-GRN PROCLAIM Phase 1/2 trial Planned Single ICM 3 month 12 month 5-year safety and injection biomarker readout clinical readout clinical follow-up FTD-GRN Patients • 30-80 years old • Single pathogenic GRN mutation PR006 • Symptomatic disease stage • Stable background medications • Safety
Slide 28: PR006 market opportunity
PR006 market opportunity FTD-GRN Disease • Progressive and devastating early-onset form of dementia Overview • Leads to death within 3-10 years Treatment & • No therapies approved for FTD Unmet Need • No therapies have shown disease modification • FTD prevalence ~50,000 in US; ~800-110,000 in EU Mar
Slide 29: CMC strategy and capabilities
CMC strategy and capabilities Established internal process development capabilities; working with CDMOs to supply clinical trials with drug product Phase 3 and Commercial Material Phase 1/2 Material • Baculovirus platform to establish high-yield scalable process • Robust adherent HEK293 process to •
Slide 30: Prevail Therapeutics summary
Prevail Therapeutics summary • Developing potentially disease-modifying gene therapies for neurodegenerative disorders • PR001 Phase 1/2 trial for PD-GBA currently recruiting • PR001 Phase 1/2 trial for nGD on track to initiate in first half of 2020 • Pipeline of gene therapy programs for neurodegen
Prevail Therapeutics — Investor Presentation (January 2020) on 6ix